The Melanocyte Lineage Factor miR-211 Promotes BRAFV600E Inhibitor Resistance
- PMID: 33504438
- PMCID: PMC7850168
- DOI: 10.1016/j.jid.2020.07.010
The Melanocyte Lineage Factor miR-211 Promotes BRAFV600E Inhibitor Resistance
Abstract
Resistance to targeted therapy and immunotherapy remains a major obstacle in improving care for patients with advanced melanoma. MicroRNAs play important roles in regulating gene networks involved in disease progression and resistance to therapy in cancers such as melanoma. MicroRNA miR-211 contributes to melanocyte and melanoma biology and has been implicated in targeted therapy resistance. Lee et al. (2020) report a novel mechanism by which miR-211 promotes resistance to BRAFV600E inhibitor therapy via the upregulation of the extracellular signal-regulated kinase 5 signaling pathway.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest
Dr. Fisher has a financial interest in Soltego, Inc., a company that is developing SIK inhibitors for topical skin darkening treatments that might be used for a broad set of human applications. Dr. Fisher’s interests were reviewed and are managed by Massachusetts General Hospital and Partners Healthcare in accordance with their conflict of interest policies.
Figures

Comment on
-
MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance.J Invest Dermatol. 2021 Feb;141(2):385-394. doi: 10.1016/j.jid.2020.06.038. Epub 2020 Sep 2. J Invest Dermatol. 2021. PMID: 32888955 Free PMC article.
Similar articles
-
MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance.J Invest Dermatol. 2021 Feb;141(2):385-394. doi: 10.1016/j.jid.2020.06.038. Epub 2020 Sep 2. J Invest Dermatol. 2021. PMID: 32888955 Free PMC article.
-
miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.Cell Commun Signal. 2020 Sep 23;18(1):156. doi: 10.1186/s12964-020-00601-1. Cell Commun Signal. 2020. PMID: 32967672 Free PMC article.
-
Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.Cancer Res Treat. 2017 Oct;49(4):947-959. doi: 10.4143/crt.2016.280. Epub 2017 Jan 3. Cancer Res Treat. 2017. PMID: 28052651 Free PMC article.
-
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?Eur J Cancer. 2016 Jul;62:76-85. doi: 10.1016/j.ejca.2016.04.005. Epub 2016 May 24. Eur J Cancer. 2016. PMID: 27232329 Review.
-
Targeted Therapy for Melanoma.Cancer Treat Res. 2016;167:251-62. doi: 10.1007/978-3-319-22539-5_10. Cancer Treat Res. 2016. PMID: 26601866 Review.
Cited by
-
circRNA18_46222157_46248185 inhibits melanogenesis by targeting miR-211/EP300 pathway in goat melanocytes.Anim Biosci. 2025 Feb;38(2):255-266. doi: 10.5713/ab.24.0316. Epub 2024 Aug 26. Anim Biosci. 2025. PMID: 39210802 Free PMC article.
-
The Multifaceted Role of miR-211 in Health and Disease.Biomolecules. 2025 Aug 1;15(8):1109. doi: 10.3390/biom15081109. Biomolecules. 2025. PMID: 40867554 Free PMC article. Review.
References
-
- Adam C, Fusi L, Weiss N, Goller SG, Meder K, Frings VG, et al. Efficient Suppression of NRAS-Driven Melanoma by Co-inhibition of ERK1/2 and ERK5 MAPK Pathways. J Invest Dermatol 2020. - PubMed
-
- Benito-Jardon L, Diaz-Martinez M, Arellano-Sanchez N, Vaquero-Morales P, Esparis-Ogando A, Teixido J. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway. Cancer Res 2019;79(9):2244–56. - PubMed
-
- Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, et al. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med 2018;24(2):203–12. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials